07/12/2026
💗 Could Vaginal Estrogen Help Reduce Serious Complications from Recurrent UTIs?
Recurrent urinary tract infections (UTIs) are more than just inconvenient—they can lead to hospitalization, sepsis, and even death, especially as women age.
A 2026 study of nearly 1.9 million women with recurrent UTIs found that women who were prescribed low-dose vaginal estrogen had significantly better outcomes than those who were not.
The study found vaginal estrogen use was associated with:
✅ 54–78% lower odds of developing sepsis (Odds Ratio 0.22–0.46)
✅ 38–69% lower odds of hospitalization (Odds Ratio 0.31–0.62)
✅ 62–80% lower odds of death (Odds Ratio 0.20–0.38)
One of the most striking findings was among women 55–69 years old:
* 1.5% mortality in women prescribed vaginal estrogen
* 7.3% mortality in women who were not prescribed vaginal estrogen
The concern?
Despite current recommendations, vaginal estrogen remains greatly underutilized:
* Only about 5% of women received a prescription within two months of being diagnosed with recurrent UTIs.
* Only about 25% were ever prescribed vaginal estrogen at all.
Current Guidelines
The 2025 American Urological Association (AUA), Canadian Urological Association (CUA), and SUFU guidelines recommend offering vaginal estrogen to peri- and postmenopausal women with recurrent UTIs who have no contraindications because it has been shown to reduce future UTI risk.
Additionally, in November 2025, the FDA removed the boxed warning from low-dose vaginal estrogen products, reflecting updated evidence regarding their safety.
If you’re experiencing:
• Frequent UTIs
• Vaginal dryness or irritation
• Pain with in*******se
• Urinary urgency or burning
• Symptoms related to menopause
It may be time to discuss whether vaginal estrogen is right for you.
